About Us

Who We Are

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors.

Our
History

Feb. 2022

Gracell Biotechnologies dosed first patients in First-in-Human clinical trial evaluating GC012F, a dual-targeting FasTCAR-T Therapy for the treatment of B-Cell Non-Hodgkin's Lymphoma
Jan. 2022

Gracell Biotechnologies unveiled Innovation Center in U.S.
Dec. 2021

Gracell Biotechnologies was selected for addition to NASDAQ Biotechnology Index
Nov. 2021

Gracell Biotechnologies was granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy candidate GC012F for the treatment of multiple myeloma
Mar. 2021

Signs agreement with Lonza to manufacture Gracell's FasTCAR product candidates in the U.S.
Jan. 2021

Completes IPO and NASDAQ listing, raising $240 million in gross proceeds
Jan. 2021

NMPA approves IND for GC019F FasTCAR™ enabled autologous CAR-T therapy for r/r adult B-ALL
Jan. 2021

Suzhou manufacturing facility receives Medical Products Manufacturing Certificate from JSMPA
Dec. 2020

NMPA approves registrational seamless Phase 1/2 clinical trial for GC007g donor-derived allogeneic CAR-T cell therapy for r/r B-ALL
Dec. 2020

Reports first-in-human data at ASH 2020 on GC012F FasTCAR-enabled dual-targeting BCMA/CD19 cell therapy in patients with r/r MM
Oct. 2020

NMPA accepts IND application for GC019F autologous CAR-T cell therapy for adult B-ALL
Oct. 2020

Closes series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures, and participation from Vivo, Temasek, LAV, Kington Capital, and Chengdu Miaoji
Aug. 2020

Suzhou GMP manufacturing facility opens
Apr. 2020

Reports data on first-in-human clinical trial of off-the-shelf TruUCAR-enabled GC027 in r/r T-ALL at AACR 2020
Apr. 2020

NMPA approves IND application for GC007g donor-derived CAR-T cell therapy for CD19 positive r/r B-ALL
Feb. 2019

Closes series B funding from Temasek, OrbiMed, Lilly Asia Ventures, Kington Capital, and Chengdu Miaoji
Oct. 2017

Shanghai R&D facility opens
May. 2017

Gracell Biotechnologies was founded by Dr. William Wei Cao and co-founding team

Management Team

William Wei Cao, Ph.D. B.M.

Founder, Chairman, and Chief Executive Officer

Martina A. Sersch, M.D., Ph.D.

Chief Medical Officer

Kevin Yili Xie, Ph.D.

Chief Financial Officer

Jenny Yajin Ni, Ph.D., M.D.

Chief Technology Officer

Board of Directors

William Wei Cao, Ph.D. B.M.

Founder, Chairman, and Chief Executive Officer

David Guowei Wang, M.D., Ph.D.

Director

Guotong Xu, M.D., Ph.D.

Director

Wendy Hayes

Director

Christophe Lee

Director